Snelders Eveline, van der Lee Henrich A L, Kuijpers Judith, Rijs Anthonius J M M, Varga János, Samson Robert A, Mellado Emilia, Donders A Rogier T, Melchers Willem J G, Verweij Paul E
Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
PLoS Med. 2008 Nov 11;5(11):e219. doi: 10.1371/journal.pmed.0050219.
Resistance to triazoles was recently reported in Aspergillus fumigatus isolates cultured from patients with invasive aspergillosis. The prevalence of azole resistance in A. fumigatus is unknown. We investigated the prevalence and spread of azole resistance using our culture collection that contained A. fumigatus isolates collected between 1994 and 2007.
We investigated the prevalence of itraconazole (ITZ) resistance in 1,912 clinical A. fumigatus isolates collected from 1,219 patients in our University Medical Centre over a 14-y period. The spread of resistance was investigated by analyzing 147 A. fumigatus isolates from 101 patients, from 28 other medical centres in The Netherlands and 317 isolates from six other countries. The isolates were characterized using phenotypic and molecular methods. The electronic patient files were used to determine the underlying conditions of the patients and the presence of invasive aspergillosis. ITZ-resistant isolates were found in 32 of 1,219 patients. All cases were observed after 1999 with an annual prevalence of 1.7% to 6%. The ITZ-resistant isolates also showed elevated minimum inhibitory concentrations of voriconazole, ravuconazole, and posaconazole. A substitution of leucine 98 for histidine in the cyp51A gene, together with two copies of a 34-bp sequence in tandem in the gene promoter (TR/L98H), was found to be the dominant resistance mechanism. Microsatellite analysis indicated that the ITZ-resistant isolates were genetically distinct but clustered. The ITZ-sensitive isolates were not more likely to be responsible for invasive aspergillosis than the ITZ-resistant isolates. ITZ resistance was found in isolates from 13 patients (12.8%) from nine other medical centres in The Netherlands, of which 69% harboured the TR/L98H substitution, and in six isolates originating from four other countries.
Azole resistance has emerged in A. fumigatus and might be more prevalent than currently acknowledged. The presence of a dominant resistance mechanism in clinical isolates suggests that isolates with this mechanism are spreading in our environment.
最近有报道称,从侵袭性曲霉病患者身上培养出的烟曲霉分离株对三唑类药物产生了耐药性。烟曲霉中唑类耐药的流行情况尚不清楚。我们利用我们的培养物收集库(其中包含1994年至2007年间收集的烟曲霉分离株)调查了唑类耐药的流行情况和传播情况。
我们调查了在14年期间从我校医学中心的1219名患者身上收集的1912株临床烟曲霉分离株中伊曲康唑(ITZ)耐药的流行情况。通过分析来自荷兰其他28个医学中心的101名患者的147株烟曲霉分离株以及来自其他六个国家的317株分离株,研究了耐药性的传播情况。使用表型和分子方法对分离株进行了鉴定。利用电子病历确定患者的基础疾病以及侵袭性曲霉病的存在情况。在1219名患者中的32名患者身上发现了ITZ耐药分离株。所有病例均在1999年之后观察到,年患病率为1.7%至6%。ITZ耐药分离株对伏立康唑、雷夫康唑和泊沙康唑的最低抑菌浓度也有所升高。发现cyp51A基因中第98位亮氨酸被组氨酸取代,同时基因启动子中有两个串联的34 bp序列(TR/L98H)是主要的耐药机制。微卫星分析表明,ITZ耐药分离株在基因上是不同的,但聚类在一起。ITZ敏感分离株导致侵袭性曲霉病的可能性并不比ITZ耐药分离株更高。在来自荷兰其他九个医学中心的13名患者(12.8%)的分离株中发现了ITZ耐药,其中69%携带TR/L98H替代,在来自其他四个国家的六株分离株中也发现了ITZ耐药。
烟曲霉中已出现唑类耐药,其流行情况可能比目前所认识的更为普遍。临床分离株中存在一种主要的耐药机制,表明具有这种机制的分离株正在我们的环境中传播。